PAR-23-032: Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants of up to $350,000 to small businesses. Applications closed on September 5, 2025.
From the official notice on Grants.gov, last changed November 6, 2023. Checked November 7, 2026.
- Award ceiling$350,000
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR43 / R44
- Clinical trialsNot allowed
- Funded byNIAMS
- Median yearly award$300,000
- Typical project length2 years
- R43, Small Business Innovation Research (SBIR) Phase I. A small business tests the feasibility of a technology or product. Other open R43 notices.
- R44, Small Business Innovation Research (SBIR) Phase II. Full research and development of an SBIR project after Phase I (or both phases at once, called Fast Track). Other open R44 notices.
Projects funded under PAR-23-032 were run by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS, 8 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-23-032 in the NIH Guide.
Key dates
| Posted | October 26, 2022 |
|---|---|
| Deadline | September 5, 2025 |
| Archived by Grants.gov | October 11, 2025 |
Who can apply
This opportunity was open to small businesses.
- Small businesses
Other Eligible Applicants include the following:Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $300,000; it allows up to $350,000 per award.
- Most of the program's money (74% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)
Funded under PAR-23-032 so far
NIH funded 8 projects under PAR-23-032 in fiscal 2023 to 2026, at 6 institutions. The median yearly award was $300,000.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| A novel bioactive bone graft to promote accelerated bone regeneration | Tissuerate Inc. | 2026 | $1.3 million |
| The Rotational Femoral Nail: Late Stage Translation from Lab to Marketplace | MDS II LLC | 2026 | $299,996 |
| A COMPLIANT ANKLE ENDOPROSTHESIS TO TREAT ANKLE-HINDFOOT PATHOLOGY | Flex Orthopaedics, Inc. | 2024 | $299,996 |
| AlloBrace: Pure Collagen Augment to Improve Performance and Integration of Allografts | Collamedix Inc. | 2024 | $300,000 |
| OsTend: A load-bearing, bi-phasic collagen scaffold for massive rotator cuff repairs | Collamedix Inc. | 2023 | $300,000 |
| CollaLink: Guided-regenerative Scaffold for Augmentation of Anterior Cruciate Ligament Repair | Collamedix Inc. | 2023 | $300,000 |
| The X-VISUAL (X-ray Visualized Indicator for Screw-strain Under Applied Load) | Aravis Biotech, LLC | 2023 | $299,999 |
| Pre-Clinical Assessment of a Minimally Invasive Meniscus Implant to Delay Arthritis | Orthopreserve, Inc. | 2023 | $303,905 |
Who has won Arthritis, Musculoskeletal and Skin Diseases Research grants before
From fiscal 2021 to 2025, Arthritis, Musculoskeletal and Skin Diseases Research (93.846) awarded $2.6 billion across 2,897 grant awards, an average of $908,766 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of the University of Pennsylvania | Pennsylvania | 104 | $104 million |
| Brigham & Womens Hospital Inc | Massachusetts | 89 | $95.7 million |
| The Regents of the University of California, San Francisco | California | 84 | $93.3 million |
| The Washington University | Missouri | 88 | $72.4 million |
| Regents of the University of Michigan | Michigan | 73 | $68.0 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-23-032 still open?
No. It closed on September 5, 2025.
Who can apply for Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)?
Closed September 5, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $350,000 each.
Who has been funded under PAR-23-032?
NIH RePORTER lists 8 projects funded under PAR-23-032 in fiscal 2023 to 2026, at 6 institutions. The most were at Collamedix Inc., Tissuerate Inc., MDS II LLC.
Who has won Arthritis, Musculoskeletal and Skin Diseases Research grants before?
The largest recipients over five fiscal years were The Trustees of the University of Pennsylvania, Brigham & Womens Hospital Inc, The Regents of the University of California, San Francisco. The program made 2,897 awards worth $2.6 billion in that time.
Similar open grants
- Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)